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Background: Millions of older adults who develop community-acquired pneumonia (CAP)
each year survive, but there is a large knowledge gap on the burden of CAP and the recovery
process in survivors from the patient perspective.
Methods: The newly developed CAP Burden of Illness Questionnaire was administered through
a Web survey to a nationwide sample of US adults aged $50 years who were recently diagnosed
with CAP. Survey respondents with unresolved symptoms or other CAP-related health problems
completed a second survey 30 days later; a third survey was completed another 30 days later by
respondents with unresolved symptoms or problems. Nationally representative results describing the average time to recovery of symptoms and other CAP-related problems were achieved
using post-stratification weights.
Results: Five hundred participants completed the initial survey. The time to resolution for the
CAP symptoms of weakness, shortness of breath, and tiredness exceeded 3 weeks on average.
There was an average of 13 days of absenteeism, and 3 weeks (mean =21 days) before achieving
full work/activity productivity after CAP. For participants with health conditions that worsened
from pneumonia, chronic emphysema and chronic obstructive pulmonary disease took the
longest to return to baseline (mean =60 and 52.4 days, respectively).
Conclusion: The results from this study demonstrate that older adults surviving a CAP episode
experience a significant multi-symptom illness with long recovery periods to achieve pre-CAP
health and productivity. These findings highlight the need for further research on effective
clinician–patient communication, the need for patient-centered outcomes in clinical trials for
CAP therapeutics, adequate home care during the recovery process, and the pursuit of CAP
prevention strategies.
Keywords: burden of illness, community-acquired pneumonia, symptoms, patient-reported
outcomes, longitudinal study, health-related quality of life
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Approximately, 950,000 cases of community-acquired pneumonia (CAP) occur in the
USA each year in adults ,65 years of age;1 concurrently, another 1.3 million cases
occur in older adults $65 years of age.2 CAP is defined as pneumonia contracted in the
community rather than in a hospital or nursing home setting, or while on a ventilator.3
With the incidence and severity of CAP increasing notably with age,4 pneumonia
remains the leading cause of infectious disease mortality in the USA.5 These data
215

submit your manuscript | www.dovepress.com

Patient Related Outcome Measures 2015:6 215–223

Dovepress

© 2015 Wyrwich et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php

http://dx.doi.org/10.2147/PROM.S85779

Dovepress

Wyrwich et al

indicate that millions of older adults in the USA survive
this disease each year, leaving a large knowledge gap on the
burden of CAP and the recovery process in survivors from
the patient perspective.
Prior studies evaluating the time to resolution of CAP
symptoms have focused on a very limited number of indicators
selected and worded by physicians.6,7 While returning to work
or other usual activities are important milestones in the recovery from CAP,8–10 diminished productivity during the CAP
recovery process may extend beyond absenteeism. There is a
need to better understand the broad range of problems associated with CAP recovery based on the patients’ experiences that
are not measured in generic health status instruments.11,12
Therefore, the CAP Burden of Illness Questionnaire
(CAP-BIQ) was developed and refined through in-depth
concept elicitation and cognitive debriefing interviews with
adults $50 years of age who had recently been diagnosed
with CAP.13 This report provides results across three successive monthly survey administrations up to 180 days after
CAP diagnosis, detailing the length of time that older adults
in the USA have CAP symptoms as well as CAP’s detrimental
effects on other health conditions and productivity.

Methods
Study design, participants, and outcome
measures
The CAP-BIQ was designed using the methodology recommended by the US Food and Drug Administration14 for the
development of patient-reported outcome measures. Details
on the development and testing of this survey instrument are
available elsewhere.13 The questionnaire was administered in
three waves, each 30 days after the preceding wave (Wave 1,
Wave 2, and Wave 3), to measure the time course of CAP
symptoms until resolution. Participants with unresolved CAP
symptoms or related CAP problems noted at Wave 1 were
followed 30 days later (Wave 2); those with any unresolved
CAP symptoms or problems at Wave 2 were followed for
an additional 30 days (Wave 3). The full CAP-BIQ is available on the Journal’s website at http://www.dovepress.com/
get_supplementary_file.php?f=85779.pdf.
Participants were recruited through an e-mail invitation
from the YouGov® panel of US adults age $50 years. For
inclusion, participants were required to: have been told by
a doctor or nurse that they had pneumonia within the past
120 days; self-report having a chest X-ray or computed
tomography (CT) scan around the time they were informed
of their diagnosis; be able to read English; and be willing
to provide informed consent. To refine CAP identification,
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participants were excluded if they had been admitted to the
hospital for any reason during the 2 weeks prior to their
diagnosis or if they resided in a nursing home or assisted care
facility. Enrollment was closed after the 500th participant
completed the Wave 1 assessment; a sample size of 500 was
chosen to give adequate precision on descriptive statistics.
This study was conducted in accordance with the amended
Declaration of Helsinki. An independent ethics and review
committee (Ethical and Independent Review Services, Independence, MO, USA) approved the protocol, and written
informed consent was obtained from all the participants.

Statistical analyses
Sample weighting was used to construct a nationally representative sample of the US adults aged $50 years. The
post-stratification weights were calculated using matching
variables for age, race/ethnicity, and education. Student’s
t-tests were used to compare mean values, and chi-square
tests for categorical data inferences. For time to resolution
of CAP-related symptoms or other issues, the mean, median,
and interquartile ranges, as well as P-values for the mean
inferential comparisons were reported. As exploratory analyses, results were stratified to compare by: age group (50–64
and $65 years old), hospitalization status (yes/no), and risk
group assignment for developing pneumonia (high risk:
the presence of asthma, COPD, chronic bronchitis, chronic
emphysema, heart disease, diabetes, or other immunocompromised conditions; low risk: none of the high-risk comorbid
conditions).15,16 Productivity and caregiver assistance results
were stratified based on self-reported employment status. All
the group comparison analyses incorporated a Bonferroni
correction to alpha to address multiplicity. The analyses were
performed in SAS version 9.1.3.

Results
The sociodemographic characteristics for all participants
in the Wave 1 (baseline) survey using the weighted sample
are fully described elsewhere.13 Briefly summarizing those
results, 45% were male, the average age was 62.4 years old,
the majority of participants reported living with a partner
(79.5%), and 89.2% selected White as their race. The mean
number of days between CAP diagnosis and Wave 1 CAPBIQ completion was 56.9 days. The mean hospital stay due
to pneumonia was 6.8 days, and 91.4% of these patients were
hospitalized on the day of diagnosis. The hospitalized group
was older and had a greater percentage of participants with
COPD, chronic emphysema, heart disease, and diabetes than
the nonhospitalized group (P,0.001). High-risk participants
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were more likely to have high blood pressure, and more than
twice as likely to be hospitalized compared to the low-risk
group (P,0.001).13

Symptom resolution
Length of time until symptom resolution for all participants
who experienced at least 1 day with a symptom is reported
in Table 1. The mean and median duration for fever (feeling
warm), chills, and sweats was less than a week, whereas the
mean time for tiredness, weakness, and shortness of breath
were at least 3 weeks. The other ten symptoms measured in
this study persisted generally for approximately 1–2 weeks.
The interquartile ranges for cough, body aches, wheezing,
and trouble sleeping show that, for at least a quarter of the
sample, it took nearly 3 weeks to achieve symptom resolution (Table 1).
Only fever/warmth and chills differed significantly
(P#0.001) between the age groups, with the younger group
experiencing the symptoms on average approximately 1–3
days longer compared to the older group. Low- and highrisk groups had significant differences only in the duration
of chills and sweats, with longer mean times (2–3 days)
observed for the low-risk group. Fever lasted nearly twice
as long on average in the nonhospitalized group compared
to those who were hospitalized, but significant differences in
mean symptom duration between these two groups indicated
an overall longer recovery time for the hospitalized group
for tiredness, body aches, and weakness.

Time to resolution of health
conditions worsened by pneumonia
For those who experienced a worsening of specific health
conditions due to pneumonia, the means, medians, and interquartile ranges for number of days to return to baseline are
reported in Table 2. Patients with chronic emphysema had the
longest duration to return to baseline (mean/median =60/65
days) followed by COPD (52/44 days); the 75th percentile levels for both of these groups were nearly 3 months
(89 days). In the subgroup with COPD, the younger group
took longer to return to their baseline COPD condition than
the older age group (P=0.004), as did hospitalized participants compared to nonhospitalized participants (P=0.025),
although these differences did not reach statistical significance when adjusted for multiplicity (P,0.003).

CAP impacts on productivity
CAP impacts on work productivity and the need for additional help are presented in Table 3. There was a greater

Patient Related Outcome Measures 2015:6

Symptom burden and recovery from CAP

proportion of nonemployed versus employed participants
who were hospitalized; however, a greater proportion of
the employed group missed work (92.5%) compared to the
proportion of the nonemployed group who missed their
usual daily activities (74.1%; P,0.001). Those who missed
days of work or usual daily activities were away on average
for 13 days. Moreover, the mean time before achieving full
work/activities productivity took nearly 3 weeks (20.1 days),
and differed between those who were employed (14.2 days)
and those who were not (24.3 days; P,0.001). As reported
in Wyrwich et al (2013), 77.4% of participants reported at
Wave 1 on the need for help with their care from family or
friends during their bout with CAP.13 On average, participants receiving this assistance had help for nearly 2 weeks
(Table 3).

Discussion
This study evaluated the contemporary experience of the
disease course of CAP in older adults in the USA by documenting the burden of illness in CAP survivors up to 180 days
after diagnosis from the patient’s perspective. Use of a newly
developed, disease-specific measure based on what patients
themselves described as important13 allowed greater detail on
the presence, duration, and impact of CAP symptoms.
The key findings demonstrate that CAP patients experience a wide variety of systemic and respiratory symptoms
that also impact the course of other comorbid illnesses. The
results also show that symptoms and impacts of symptoms
can last for days to months after onset of illness, imposing a
burden on patients and on their caregivers and/or partners.
Of the 16 symptoms measured, half took more than 2 weeks,
on average, to resolve; the time to resolution for weakness,
shortness of breath, and tiredness exceeded 3 weeks. There
was also a delay of approximately 3 weeks in achieving full
productivity at work or usual activities.
The length of time to resolution for most longer-lasting
symptoms did not differ between participants in the younger
and older age groups, or between the low- and high-risk
groups. However, for tiredness, body aches, weakness, and
trouble sleeping, resolution was nearly 1 week longer for
those who were hospitalized compared to those who were not
hospitalized. In contrast, early-resolving symptoms of fever/
warmth, sweats, or chills lasted longer in nonhospitalized or
younger, and low-risk subgroups compared to their respective
counterparts. Because CAP is caused by pathogenic organisms infecting the pulmonary parenchyma with resultant
host inflammatory response,17,18 the relatively long duration
of some symptoms may reflect prolonged host response that
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4.9, 2 [2, 7]
5.4, 2 [2, 7]
5.5, 2 [2, 7]
14.8, 12 [7, 20]
12.2, 7 [2, 14]

13.8, 7 [7, 14]
20.8, 14 [7, 21]
11.3, 7 [2, 14]
15.6, 9 [2, 20]
24.2, 19 [9, 21]
23, 14 [7, 21]
10.1, 7 [2, 7]
13.3, 7 [2, 14]
8.4, 7 [2, 7]
18.6, 14 [7, 20]
21.4, 8 [7, 21]

4.4, 2 [1, 7]
5.2, 2 [2, 7]
15.4, 9 [7, 20]
12.7, 7 [2, 14]

15.3, 7 [7, 15]

21.2, 14 [7, 21]
9.9, 7 [2, 14]
15.7, 8 [2, 20]

24.4, 18 [7, 23]
22.8, 14 [7, 21]

9.6, 7 [2, 7]
14, 7 [2, 14]

9.2, 7 [2, 8]

18.6, 14 [7, 20]
20.5, 8 [7, 21]

Mean, median
[25th and 75th
percentile]
of time with
symptom

Mean, median
[25th and 75th
percentile]
of time with
symptom

4.3, 2 [2, 7]

Age 50–64
N=289

All
N=500

18.6, 14 [7, 20]
19.2, 7 [2, 20]

11.1, 7 [7, 14]

8.4, 6 [2, 7]
15.2, 7 [2, 14]

24.7, 14 [7, 24]
22.4, 14 [7, 21]

21.9, 14 [7, 21]
7.2, 2 [2, 7]
15.7, 7 [2, 20]

17.3, 7 [7, 20]

2.5, 2 [1, 2]
4.5, 2 [1, 2]
16.2, 7 [6, 16]
13.5, 7 [2, 14]

3.2, 2 [1, 2]

Mean, median
[25th and 75th
percentile]
of time with
symptom

Age 65+
N=211

0.989
0.468

0.265

0.530
0.313

0.823
0.804

0.580
0.062
0.936

0.096

0.001
0.457
0.428
0.458

0.038

P-value for
comparison
of mean
time with
symptom

16.6, 14 [7, 18]
17.3, 7 [7, 20]

10.1, 7 [2, 14]

11.6, 7 [2, 7]
15, 7 [7, 14]

21.4, 14 [7, 21]
21.1, 14 [7, 21]

18.7, 14 [7, 21]
9.9, 7 [2, 14]
13.2, 7 [2, 20]

15.6, 7 [7, 19]

4.7, 2 [2, 7]
6.0, 2 [2, 7]
16.6, 14 [7, 20]
12.5, 7 [2, 14]

5.3, 2 [2, 7]

Mean, median
[25th and 75th
percentile]
of time with
symptom

Nonhospitalized
N=299

21.7, 11 [7, 21]
24.9, 11 [6, 21]

8.1, 7 [2, 8]

7.3, 2 [2, 7]
12.6, 7 [2, 14]

28.9, 20 [11, 43]
25.1, 14 [7, 43]

25, 20 [7, 24]
10, 7 [2, 9]
19.5, 9 [2, 21]

14.8, 7 [7, 14]

3.9, 2 [1, 2]
4.0, 2 [1, 7]
13.6, 7 [2, 14]
12.9, 7 [2, 14]

2.7, 2 [1, 2]

Mean, median
[25th and 75th
percentile]
of time with
symptom

Hospitalized
N=201

0.0260
0.0100

0.356

0.084
0.208

0.001
0.105

0.001
0.982
,0.001

0.721

0.405
0.116
0.089
0.818

0.001

P-value for
comparison
of mean
time with
symptom

16, 14 [7, 20]
17.2, 14 [7, 20]

9.6, 7 [2, 14]

8.6, 7 [2, 7]
15.7, 14 [7, 18]

22.4, 20 [14, 21]
19.2, 14 [7, 20]

18.6, 14 [7, 21]
9.1, 7 [2, 7]
14.2, 14 [7, 20]

17.6, 14 [7, 21]

6.3, 2 [2, 7]
7.3, 2 [2, 7]
17.3, 14 [7, 21]
14.6, 7 [7, 20]

5.1, 2 [2, 7]

Mean, median
[25th and 75th
percentile]
of time with
symptom

Low riskb
N=137

19.5, 11 [7, 20]
21.5, 7 [6, 21]

9.1, 7 [2, 8]

10, 3 [2, 7]
13.4, 7 [2, 14]

25.2, 16 [7, 27]
23.9, 14 [6, 39]

22.2, 14 [7, 21]
10.3, 7 [2, 14]
16.2, 7 [2, 20]

14.4, 7 [7, 14]

3.7, 2 [1, 2]
4.3, 2 [1, 7]
14.7, 7 [2, 14]
11.9, 7 [2, 14]

3.9, 2 [1, 7]

Mean, median
[25th and 75th
percentile]
of time with
symptom

High riskc
N=363

0.176
0.203

0.843

0.599
0.275

0.274
0.097

0.104
0.612
0.321

0.165

0.006
0.022
0.177
0.148

0.154

P-value
for comparison
of mean time
with symptom

Notes: aFor those without symptom resolution, the time since CAP diagnosis to last survey was used in this calculation; blow risk, none of the high-risk comorbid conditions listed in the chigh-risk description: chronic bronchitis, chronic
emphysema, heart disease, diabetes, or other immunocompromised conditions.
Abbreviation: CAP, community-acquired pneumonia.

Fever/warmth
(67.4%)
Chills (64.9%)
Sweats (58.9%)
Cough (94.0%)
Chest, back,
stomach, shoulder,
or rib pain from
coughing (75.6%)
Mucus or phlegm
(81.6%)
Tiredness (97.5%)
Headaches (40.1%)
Body aches
(84.5%)
Weakness (96.3%)
Shortness of
breath (90.5%)
Confusion (35.1%)
Weak appetite
(82.2%)
Gastric symptoms
(34.5%)
Wheezing (85.4%)
Trouble sleeping
(71.6%)

Symptom
(with
symptom
at diagnosis
of CAP)

Table 1 Days until symptom resolutiona among participants who reported at least 1 day with symptom
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13.1, 7 [2–14]
44.8, 30 [14–44] 12.1, 14 [7–21]
20.3, 14 [7–22]
16.3, 7 [7–14]
57.3, 21 [14–109] 37.9, 14 [7–74]

16.1, 7 [2–14]

38.7, 29 [7–30]
18.0, 7 [7–21]
49.3, 21 [7–109]

19.0, 7 [7–21]

67.8, 69 [44–114] 41.2, 18 [7–89]

60, 65 [7–89]

Mean, median
[25th and 75th
percentile]
of time until
normal

21.6, 14 [7–30]
29.1, 21 [14–30]
65.2, 69 [21–102] 39.5, 14 [7–74]
27.5, 14 [7–21]
40.5, 21 [7–60]

Mean, median
[25th and 75th
percentile]
of time until
normal

Mean, median
[25th and 75th
percentile]
of time until
normal

Age 65+
N=211

24.8, 14 [7–30]
52.4, 44 [7–89]
32.8, 18 [7–30]

Age 50–64
N=289

All
N=500

0.193
0.647
0.196

0.221

0.114

0.254
0.004
0.247

P-value for
comparison
of mean
time with
worsened
health
condition

24.8, 14 [7–30]

70.1, 78 [55–89]

30.6, 21 [14–30]
60.6, 69 [14–98]
34.2, 21 [14–30]

Mean, median
[25th and 75th
percentile]
of time until
normal

Hospitalized
N=201

7.9, 2 [2–14]
49.3, 30 [26–44]
21.3, 14 [7–30]
15.4, 7 [7–14]
59.9, 30 [14–109] 41.1, 21 [7–74]

10.5, 7 [2–14]

45.5, 40 [2–77]

20.9, 14 [7–22]
40.1, 14 [7–76]
31.6, 7 [7–30]

Mean, median
[25th and 75th
percentile]
of time until
normal

Non
hospitalized
N=299

0.058
0.488
0.209

0.003

0.11

0.137
0.025
0.814

P-value for
comparison
of mean
time with
worsened
health
condition

–
–
52.6, 21 [7–109]

7.0, 7 [2–7]

–

–
–
–

Mean, median
[25th and 75th
percentile]
of time until
normal

Low riskb
N=137

38.7, 29 [7–30]
18.0, 7 [7–21]
48.3, 21 [7–74]

21.6, 14 [7–30]

60, 65 [7–89]

24.8, 14 [7– 30]
52.4, 44 [7–89]
32.8, 18 [7–30]

Mean, median
[25th and 75th
percentile]
of time until
normal

High riskc
N=363

NA
NA
0.813

0.003

NA

NA
NA
NA

P-value for
comparison
of mean
time with
worsened
health
condition

Notes: aFor those without resolution, the time since CAP diagnosis to last survey was used in this calculation; blow risk, none of the high-risk comorbid conditions listed in the chigh-risk description: COPD, chronic bronchitis, chronic
emphysema, heart disease, diabetes, or other immunocompromised conditions.
Abbreviations: CAP, community-acquired pneumonia; NA, not applicable.

Asthma (23.0%)
COPD (24.4%)
Chronic bronchitis
(12.2%)
Chronic emphysema
(8.6%)
High blood pressure
(20.1%)
Heart disease (5.9%)
Diabetes (9.8%)
Other (8.5%)

Health condition
(with health
condition
worsened by
CAP)

Table 2 Days until symptom resolutiona among participants with health conditions worsened by pneumonia
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Table 3 Impact of community-acquired pneumonia on absenteeism, productivity, and help from caregiver by employment status
Impacts on productivity and need for additional help

All
N=500

Employed
N=161

Not employed
N=339

P-value for
comparison

% hospitalized
% who missed work or other usual daily activities
Number of days of work or other usual daily activities missed
due to pneumonia
Mean, median [25th and 75th percentile]
Number of days until reached usual performance level in work
or other usual daily activities
Mean, median [25th and 75th percentile]

40.29%
79.99%
12.9, 8 [5–14]

29.98%
92.48%
9.8, 7 [4–14]

45.19%
74.06%
14.7, 10 [6–15]

0.001a
,0.001a
,001b

20.1, 14 [7–21]

14.2, 14 [7–14]

24.3, 14 [7–21]

,0.001b

Percent with family or friends helping with care during pneumonia
Number of days of family or friends helping with care during pneumonia
Mean, median [25th and 75th percentile]

77.41%
13.7, 7 [2–14]

80.83%
7.5, 7 [2–7]

75.79%
16.9, 7 [6–18]

0.208a
,0.001b

Notes: aP-value for percentage comparison; bP-value for mean comparison.

is persistent even after immunological response and control
of the causative organisms. The magnitude and duration of
host response may differ in different types of patients, with
or without antibiotics.
For participants who reported that CAP worsened their
comorbid conditions, many of the symptoms of these conditions were affected for more than a month; younger or hospitalized participants with worsened COPD were generally
affected for more than 2 months. Our results are consistent
with prior investigations showing that over 35% of adults
with CAP at low risk of death have unresolved CAP-related
symptoms 1 month post-diagnosis.7
Our findings are also consistent with other studies showing: 1) older patients who survive CAP on average had similar
symptoms but different severity or duration of symptoms than
younger patients because of the former’s diminished ability
to mount a robust immune response,19,20 2) CAP patients
with other coexisting health conditions had significantly
impaired general quality of life compared to CAP patients
without underlying diseases,21 and 3) a median time to return
to work of 7 days for outpatients and 14 days for inpatients
in low-risk CAP patients.8 Although time to return to full
work/activity productivity has not been assessed in previous
studies, the 3 weeks needed to return to full productivity even
after return to work highlights the impact of CAP beyond
traditional productivity measures.
This study has some important limitations. As in previous
recovery studies,6,22 this study used retrospective recall of
symptoms, which can be subject to recall bias.23,24 To recruit
a sufficient sample of older adults with CAP, a window
of up to 120 days between diagnosis and Wave 1 survey
completion was necessary. To address the issue of recall
bias, prospective studies on the burden of CAP in patients
who are surveyed soon after diagnosis are needed to assess
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the duration of specific CAP symptoms and functioning.
Such studies are currently underway based on the work
in this study.25 The use of self-report for the diagnosis of
pneumonia is also a limitation, although patients are likely
to correctly remember a seminal event like the diagnosis of
this potentially life-threatening illness.26,27 We attempted to
minimize case identification error by asking patients if they
had a radiologically confirmed diagnosis – as radiography
is another event that patients aged $50 years are likely to
accurately recall.28–30 Other studies have also used self-report
of pneumonia diagnosis,31–33 one of which showed high concordance (82%) between self-diagnosis and medical chart
and radiographic confirmation of diagnosis.31 Moreover, if
there was overdiagnosis of pneumonia in the current study
because of contamination by patients with bronchitis or
other self-resolving disease, the results would most likely
underestimate the burden of symptoms.34 Another potential
limitation that might bias the study results would be if the
older adults with CAP in the YouGov® panel are different
from the US general population for this age group in ways
that cannot be fully adjusted for with the demographic
weights that were used. Lastly, our study focused solely on
CAP survivors and may not reflect the presence of symptoms
at baseline in CAP patients who did not survive their bout
with pneumonia. Therefore, there may be survivor bias in the
comparisons of younger versus older patients and hospitalized versus nonhospitalized patients if older, hospitalized
patients have greater mortality. Regardless, our results are
accurate in terms of the clinical course of patients who will
be seen in practice by clinicians, since they represent the
population of survivors.
In addition, although CAP-BIQ captures data to provide a comprehensive picture of the course of illness and
disease impact from the patient’s perspective, this lengthy
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questionnaire may not be appropriate as an outcome
measure in clinical trials testing treatment effects of various interventions for pneumonia. Nonetheless, the results
from this patient-reported outcome questionnaire can
inform the development of a shorter instrument for use
in clinical trials measuring CAP impact at diagnosis and
recovery. This work based on CAP-BIQ is the basis for
ongoing studies to prospectively develop a patient-reported
outcome for clinical trials in patients with radiographically
confirmed CAP.25
Despite these limitations, this study offers many key
insights into patients’ experiences with CAP. A major strength
of the study is the documentation of the content validity and
understandability of the survey instrument before its use
in this study, demonstrating a wide array of symptoms not
captured in previous studies.13 Moreover, few studies have
examined the long-term effects of CAP beyond the first
month after diagnosis. Employing a broad Web panel provided for nationwide enrollment. The use of a single method
of administration for the survey also eliminates potential
bias due to a mixing of methods (eg, Web survey, paper and
pencil, etc). In addition, knowledge of the participants’ age,
race/ethnicity, and education aided in the construction of
post-stratification weights matching the US population aged
$50 years, and corrected for any demographic skewness in
the sample.
With this evidence from a patient perspective on the
range of CAP symptoms, functional limitations, and time
necessary to fully recover, our results can have an impact on
clinical practice. Greater understanding of the natural history
of CAP can aid both patients and clinicians in better managing episodes beyond the acute phase of the disease. Our data
show a broader range of symptoms than cough, chest pain,
and dyspnea, which are usually associated with pneumonia,
indicating that clinicians should inquire about a broader range
of symptoms. Symptoms often persist longer than a month,
which exceeds the time when patients complete antibiotic
therapy. Therefore, patients should be informed that they may
continue to experience the residual effects of pneumonia long
beyond the period of active treatment. Patient knowledge of
the course of the treated disease allows for realistic expectations of the recovery trajectory, and may reduce unnecessary
health care use and inappropriate antibiotic prescribing for
apparent relapses that actually represent the natural course
of the illness. A previous study reported greater pneumoniarelated ambulatory care visits6 with greater symptom burden
during CAP recovery, independent of the pneumonia severity
or comorbidities.
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These results also demonstrate that adequate home care
for a sufficient period is a key consideration, one that needs
to be addressed either at the time of diagnosis (outpatient
recovery) or during hospitalization prior to discharge.
The seriousness and disability associated with CAP over
an extended period is evidenced by 77% of the study population receiving informal care from family or friends for
almost 2 weeks. Given that 30-day pneumonia readmission
rate is tracked as an indicator of quality and coordination of
care by the Center for Medicare and Medicaid Services,35
providers should involve caregivers in the post-discharge
planning and follow-up to reduce ambulatory care-sensitive
readmissions.
Our results also provide evidence to inform future
research efforts. Future studies may evaluate whether some
treatments have greater effects than others in decreasing various symptoms associated with CAP. Current studies focus
solely on resolution of a small number of early-resolving
symptoms (eg, chest pain, cough, and dyspnea); yet the
demand for patient-centered outcomes fully reflecting the
patient’s experience has become a major impetus in health
care reform.36 Therefore, description of treatment effects on
the spectrum of important CAP symptoms deserves further
attention. Our results show a wider range of symptoms in
pneumonia than are usually captured in clinician-reported
outcomes in the clinical trials of CAP.
Finally, in addition to the substantial number of CAP
deaths annually, this documented burden of illness among
CAP survivors emphasizes the importance of CAP prevention in older adults to avoid the prolonged disability
associated with this disease. Recommended prevention
strategies include smoking cessation, annual influenza vaccination, pneumococcal vaccine for adults aged $65 years
and those ,65 years old who have underlying medical
conditions, and educational support for these vulnerable
populations.37

Conclusion
This study demonstrated that older adults surviving a CAP
episode experience a significant multi-symptom illness with
long recovery period before achieving pre-CAP health and
productivity. These findings highlight the importance of communicating the natural course of the illness to inform patient
and clinician expectations, the need for further research on
effective clinician–patient communication, adequate home
care during the recovery process, better patient-centered
outcomes in evaluating therapies for CAP, and the pursuit
of CAP prevention strategies.
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